Our News Library | Levin Papantonio - Personal Injury Lawyers

At Conference, Merck Responds to FDA Inquiries About Fosamax

ADELPHI, MD

At today's FDA Panel conference on the long term use of osteoporosis drugs like Fosamax, presenter Arthur C. Santora MD, PhD, speaking for Merck, the drug manufacturer, attempted to convince the panel that limits on the duration of the drugs use were not necessary. However, Dr. Santora did admit that drug "holiday" (meaning a temporary interruption in usage) may be considered for patients who are no longer considered to have a sufficiently high fracture risk.

read more

FDA Presents Data for Long-Term Fosamax Use

ADELPHI, MD

In the early morning session of today's FDA Panel conference on the long term use of bisphosphonates, like the drug Fosamax, the FDA's Lead Medical Officer Fatmatta Kuyateh, M.D. indicated that radiographic findings consistent with atypical femur fractures case have been associated with bisphosphonate use.

read more

Prescription Drug User Fee Act (PDUFA): friend or foe?

Drug companies to pay the FDA $100 million in additional fees.  The upside (or is it?): 2,000 regulators get to keep their job and new drugs will continue to funnel into the market.  The downside: the FDA will increase its staff and drug companies get additional face time during the drug review process.   The last PDUFA reauthorization in 2007 was highly disputed when the FDA failed to monitor dangerous drugs such as Vioxx.

 

read more

What Does It Take?

by

K.J. McElrath

 

What constitutes proof of a conspiracy? And what does it take to demonstrate that a toxic substance actually does cause disease?

 

It is no secret – at least to those who are paying attention – that in the U.S. (and increasingly, around the world), rights and protections for natural human beings are being stripped away while at the same time, corporations are given more rights, more protections – and a whole lot less accountability.

 

read more

How Do You Fight Nature?

by

K.J. McElrath

 

Most asbestos exposure is the result of industrial use as well as construction, ship building, electronics, automotive manufacture and servicing, aviation...the list goes on and on and on.

read more

Actos – The Next Asbestos?

Although asbestos continues to be a source of illness – and the litigation that results from it – there is seemingly no end to product liability.

read more

The Recalled DePuy ASR Hip - When Did DePuy and Johnson & Johnson know they were defective?

 

By Levin Papantonio Attorney Daniel Nigh

I’ve spoken with a few prospective clients who have felt bad for DePuy and Johnson & Johnson.  They thought that the corporations had good intentions with these recalled hips and just all of a sudden found out these hips were bad and immediately recalled them.  However, that couldn’t be further from the truth.  These major corporations put profit over the safety of the patients.

read more

Florida Supreme Court lets Engle progeny case jury award stand

In the first case of the so-called Engle progeny to reach the Florida Supreme Court, the court has declined to review a lower court’s decision upholding $3.3 million in compensatory damages and $25 million in punitive damages for the widow of a smoker. (R.J. Reynolds Tobacco Co. v. Martin, No. SC11-483 (Fla. July 19, 2011).)

read more

Florida Supreme Court Blocks Tobacco Appeal

, Herald-Tribune

TALLAHASSEE

In a decision with huge implications for lawsuits against tobacco companies, the Florida Supreme Court on Tuesday declined to hear R.J. Reynolds’ appeal of a $28.3 million verdict in the death of a Panhandle smoker.

read more

LP Wins Tobacco Appeal

Court ruling may be big help for smoker plaintiffs

Law.com

Legal / Law Matters
Jose Pagliery, Daily Business Review, On Thursday December 16, 2010, 3:02 am

read more

LP Client Obtains $8 Million Jury Verdict in Fosamax Injury Case

[New York, N.Y., June 25, 2010] A jury in the United States District Court for the Southern District of New York found that Merck's osteoporosis drug Fosamax was defectively designed and unreasonably dangerous. As reported in the Wall St. Journal, the jury verdict raises serious questions about the safety of Fosamax for some patients. A medication widely prescribed for loss of bone density which might lead to osteoporosis, Fosamax has been linked not only to osteonecrosis of the jaw (a rotting of the jaw bone), but also more recently to serious fractures of the femur.

read more

Pages